<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002703</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064503</org_study_id>
    <secondary_id>PROG-9509</secondary_id>
    <nct_id>NCT00002703</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer</brief_title>
  <official_title>A PHASE III TRIAL EMPLOYING CONFORMAL PHOTONS WITH PROTON BOOST IN EARLY STAGE PROSTATE CANCER: CONVENTIONAL DOSE COMPARED TO HIGH DOSE IRRADIATION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proton Radiation Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells.

      PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation
      therapy with high-dose radiation therapy in treating men with stage I or stage II prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether high-dose radiotherapy using conformal photons with a proton
      boost produces a 20% increase in the proportion of Stage I/II prostate cancer free from local
      failure and biochemical relapse at 5 years when compared to results of conventional-dose
      radiotherapy. II. Determine whether high-dose radiotherapy produces a 33% reduction in the
      cumulative incidence of a rising PSA (second hormone failure) following hormone therapy given
      at the time of first PSA/clinical failure when compared with conventional-dose radiotherapy.
      IV. Assess the relative rectal, bladder, and sexual morbidity of conformal photon doses of
      70.2 and 79.2 Gy in these patients. V. Collect, in a prospective manner, paraffin biopsy
      blocks for subsequent analysis of emerging molecular pathologic predictors of outcome in
      three patients.

      OUTLINE: Randomized study. Arm I: Radiotherapy. Boost to the prostate using high-LET protons
      followed by irradiation of the prostate, periprostatic tissues, and seminal vesicles using
      conformal photons with energies greater than 6 MV. Conventional dose. Arm II: Radiotherapy.
      As in Arm I. High dose.

      PROJECTED ACCRUAL: There will be 390 patients accrued into this study over 3 years. An
      additional 3.5 years will be required for follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1996</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>high-LET heavy ion therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Primary
        tumor confined to prostate TNM clinical Stages T1b-c or T2a-b No T1a No T1b-c tumor with
        Gleason grade 1-2/5 No Gleason grade 1-2/5 and PSA less than 4 ng/mL Nodes negative on
        imaging (Nx) or by surgical sampling (N0) PSA no greater than 15 ng/mL Treatment must begin
        within 28 days after randomization

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 70%-100% Life
        expectancy: Greater than 10 years Other: No major medical or psychiatric illness that
        precludes protocol entry No prior or concurrent second malignancy within 5 years except
        basal cell skin cancer

        PRIOR CONCURRENT THERAPY: No prior treatment for prostate cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony L. Zietman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, Shipley WU. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e25-31. doi: 10.1016/j.ijrobp.2011.01.039. Epub 2011 Apr 4.</citation>
    <PMID>21470787</PMID>
  </results_reference>
  <results_reference>
    <citation>Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1081-5. doi: 10.1016/j.ijrobp.2009.09.015. Epub 2010 Mar 6.</citation>
    <PMID>20207497</PMID>
  </results_reference>
  <results_reference>
    <citation>Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010 Mar 1;28(7):1106-11. doi: 10.1200/JCO.2009.25.8475. Epub 2010 Feb 1.</citation>
    <PMID>20124169</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi CJ, Zietman AL, DeSilvio M, et al.: A randomized trial comparing conventional dose (70.2GyE) and high-dose (79.2GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. [Abstract] American Society of Clinical Oncology 2005 Prostate Cancer Symposium, 17-19 February 2005, Orlando, Florida. A-58, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9. Erratum in: JAMA. 2008 Feb 27;299(8):899-900.</citation>
    <PMID>16160131</PMID>
  </results_reference>
  <results_reference>
    <citation>Zietman AL, DeSilvio M, Slater JD, et al.: A randomized trial comparing conventional dose (70.2GyE) and high-dose (79. 2GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. [Abstract] Int J Radiat Oncol Biol Phys 60 (Suppl 1): A-4, S131, 2004.</citation>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 31, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2004</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

